04:21 AM EDT, 05/21/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Tuesday it is targeting total revenue of $80 billion by 2030, up from $45.8 billion in 2023, through portfolio expansion and the expected launch of 20 new medicines before the decade ends.

The company plans to hit a mid-30s percentage core operating margin by 2026, after which the margin will be "influenced by portfolio evolution and the company will target at least the mid-30s percentage range," it said.

"We are planning to launch 20 new medicines by 2030, many with the potential to generate more than $5 billion in peak year revenues," Pascal Soriot, chief executive officer of AstraZeneca ( AZN ), said.

Price: 77.00, Change: -0.11, Percent Change: -0.14